1
|
Qin X. Antibacterial Agents May Have Shifted Impacts on Inflammatory Bowel Diseases Along with Decrease in Gut Bacteria. Inflamm Bowel Dis 2024; 30:1228-1231. [PMID: 38457489 DOI: 10.1093/ibd/izae043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/31/2022] [Indexed: 03/10/2024]
Abstract
Lay Summary
This article discussed the likely bell-shaped complicated impacts of antibacterial agents such as food additives like some artificial sweeteners on inflammatory bowel diseases including ulcerative colitis and Crohn’s disease along with decrease in gut bacteria.
Collapse
Affiliation(s)
- Xiaofa Qin
- GI Biopharam Inc, 918 Willow Grove Road, Westfield, NJ 07090, USA
| |
Collapse
|
2
|
Potential Effects of Sucralose and Saccharin on Gut Microbiota: A Review. Nutrients 2022; 14:nu14081682. [PMID: 35458244 PMCID: PMC9029443 DOI: 10.3390/nu14081682] [Citation(s) in RCA: 21] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2022] [Revised: 04/08/2022] [Accepted: 04/14/2022] [Indexed: 02/06/2023] Open
Abstract
Artificial sweeteners are additives widely used in our diet. Although there is no consensus, current evidence indicates that sucralose and saccharin could influence the gut microbiota. The aim of this study was to analyze the existing scientific evidence on the effects of saccharin and sucralose consumption on gut microbiota in humans. Different databases were used with the following search terms: sweeteners, non-caloric-sweeteners, sucralose, splenda, saccharin, sugartwin, sweet’n low, microbiota, gut microbiota, humans, animal model, mice, rats, and/or in vitro studies. In vitro and animal model studies indicate a dose-dependent relationship between the intake of both sweeteners and gut microbiota affecting both diversity and composition. In humans, long-term study suggests the existence of a positive correlation between sweetener consumption and some bacterial groups; however, most short-term interventions with saccharin and sucralose, in amounts below the ADI, found no significant effect on those groups, but there seems to be a different basal microbiota-dependent response of metabolic markers. Although studies in vitro and in animal models seem to relate saccharin and sucralose consumption to changes in the gut microbiota, more long-term studies are needed in humans considering the basal microbiota of participants and their dietary and lifestyle habits in all population groups. Toxicological and basal gut microbiota effects must be included as relevant factors to evaluate food safety and nutritional consequences of non-calorie sweeteners. In humans, doses, duration of interventions, and number of subjects included in the studies are key factors to interpret the results.
Collapse
|
3
|
Méndez-García LA, Bueno-Hernández N, Cid-Soto MA, De León KL, Mendoza-Martínez VM, Espinosa-Flores AJ, Carrero-Aguirre M, Esquivel-Velázquez M, León-Hernández M, Viurcos-Sanabria R, Ruíz-Barranco A, Cota-Arce JM, Álvarez-Lee A, De León-Nava MA, Meléndez G, Escobedo G. Ten-Week Sucralose Consumption Induces Gut Dysbiosis and Altered Glucose and Insulin Levels in Healthy Young Adults. Microorganisms 2022; 10:microorganisms10020434. [PMID: 35208888 PMCID: PMC8880058 DOI: 10.3390/microorganisms10020434] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2022] [Revised: 02/03/2022] [Accepted: 02/09/2022] [Indexed: 02/04/2023] Open
Abstract
Sucralose consumption alters microbiome and carbohydrate metabolism in mouse models. However, there are no conclusive studies in humans. Our goals were to examine the effect of sucralose consumption on the intestinal abundance of bacterial species belonging to Actinobacteria, Bacteroidetes, and Firmicutes and explore potential associations between microbiome profiles and glucose and insulin blood levels in healthy young adults. In this open-label clinical trial, volunteers randomly drank water, as a control (n = 20), or 48 mg sucralose (n = 20), every day for ten weeks. At the beginning and the end of the study, participants were subjected to an oral glucose tolerance test (OGTT) to measure serum glucose and insulin every 15 min for 3 h and provided fecal samples to assess gut microbiota using a quantitative polymerase chain reaction. Sucralose intake altered the abundance of Firmicutes without affecting Actinobacteria or Bacteroidetes. Two-way ANOVA revealed that volunteers drinking sucralose for ten weeks showed a 3-fold increase in Blautia coccoides and a 0.66-fold decrease in Lactobacillus acidophilus compared to the controls. Sucralose consumption increased serum insulin and the area under the glucose curve compared to water. Long-term sucralose ingestion induces gut dysbiosis associated with altered insulin and glucose levels during an OGTT.
Collapse
Affiliation(s)
- Lucía A. Méndez-García
- Laboratory of Immunometabolism, Research Division, General Hospital of Mexico, Mexico City 06720, Mexico; (L.A.M.-G.); (R.V.-S.)
| | - Nallely Bueno-Hernández
- Laboratory for Proteomics and Metabolomics, General Hospital of Mexico, Mexico City 06720, Mexico; (N.B.-H.); (K.L.D.L.); (V.M.M.-M.); (A.J.E.-F.); (M.C.-A.); (M.E.-V.); (M.L.-H.)
| | - Miguel A. Cid-Soto
- Immunogenomics and Metabolic Diseases Laboratory, Instituto Nacional de Medicina Genómica, Mexico City 14610, Mexico;
| | - Karen L. De León
- Laboratory for Proteomics and Metabolomics, General Hospital of Mexico, Mexico City 06720, Mexico; (N.B.-H.); (K.L.D.L.); (V.M.M.-M.); (A.J.E.-F.); (M.C.-A.); (M.E.-V.); (M.L.-H.)
| | - Viridiana M. Mendoza-Martínez
- Laboratory for Proteomics and Metabolomics, General Hospital of Mexico, Mexico City 06720, Mexico; (N.B.-H.); (K.L.D.L.); (V.M.M.-M.); (A.J.E.-F.); (M.C.-A.); (M.E.-V.); (M.L.-H.)
| | - Aranza J. Espinosa-Flores
- Laboratory for Proteomics and Metabolomics, General Hospital of Mexico, Mexico City 06720, Mexico; (N.B.-H.); (K.L.D.L.); (V.M.M.-M.); (A.J.E.-F.); (M.C.-A.); (M.E.-V.); (M.L.-H.)
| | - Miguel Carrero-Aguirre
- Laboratory for Proteomics and Metabolomics, General Hospital of Mexico, Mexico City 06720, Mexico; (N.B.-H.); (K.L.D.L.); (V.M.M.-M.); (A.J.E.-F.); (M.C.-A.); (M.E.-V.); (M.L.-H.)
| | - Marcela Esquivel-Velázquez
- Laboratory for Proteomics and Metabolomics, General Hospital of Mexico, Mexico City 06720, Mexico; (N.B.-H.); (K.L.D.L.); (V.M.M.-M.); (A.J.E.-F.); (M.C.-A.); (M.E.-V.); (M.L.-H.)
| | - Mireya León-Hernández
- Laboratory for Proteomics and Metabolomics, General Hospital of Mexico, Mexico City 06720, Mexico; (N.B.-H.); (K.L.D.L.); (V.M.M.-M.); (A.J.E.-F.); (M.C.-A.); (M.E.-V.); (M.L.-H.)
| | - Rebeca Viurcos-Sanabria
- Laboratory of Immunometabolism, Research Division, General Hospital of Mexico, Mexico City 06720, Mexico; (L.A.M.-G.); (R.V.-S.)
- PECEM, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico
| | | | - Julián M. Cota-Arce
- Department of Biomedical Innovation, Center for Scientific Research and Higher Education of Ensenada (CICESE), Baja California 22860, Mexico; (J.M.C.-A.); (A.Á.-L.); (M.A.D.L.-N.)
| | - Angélica Álvarez-Lee
- Department of Biomedical Innovation, Center for Scientific Research and Higher Education of Ensenada (CICESE), Baja California 22860, Mexico; (J.M.C.-A.); (A.Á.-L.); (M.A.D.L.-N.)
| | - Marco A. De León-Nava
- Department of Biomedical Innovation, Center for Scientific Research and Higher Education of Ensenada (CICESE), Baja California 22860, Mexico; (J.M.C.-A.); (A.Á.-L.); (M.A.D.L.-N.)
| | - Guillermo Meléndez
- Facultad de Salud Pública y Nutrición, Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico
- Correspondence: (G.M.); (G.E.); Tel.: +52-552-789-2000 (ext. 5646) (G.E.)
| | - Galileo Escobedo
- Laboratory of Immunometabolism, Research Division, General Hospital of Mexico, Mexico City 06720, Mexico; (L.A.M.-G.); (R.V.-S.)
- Correspondence: (G.M.); (G.E.); Tel.: +52-552-789-2000 (ext. 5646) (G.E.)
| |
Collapse
|
4
|
Qin X. More Epidemiological Studies Warranted to Determine the Cause of Inflammatory Bowel Disease. Inflamm Bowel Dis 2021; 27:e43-e44. [PMID: 33331632 DOI: 10.1093/ibd/izaa329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/09/2022]
Affiliation(s)
- Xiaofa Qin
- GI Biopharma Inc, Westfield, New Jersey, USA
| |
Collapse
|